Henrik Suttmann

Eppendorf, HH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.

Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.

Journal: Prostate cancer and prostatic diseases

Published: May 30, 2023

LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.

LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.

Journal: Prostate cancer and prostatic diseases

Published: February 04, 2022

Management of testosterone in advanced hormone-sensitive prostate cancer: still up to date?

Management of testosterone in advanced hormone-sensitive prostate cancer: still up to date?

Journal: Aktuelle Urologie

Published: September 23, 2021

TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

Journal: Aktuelle Urologie

Published: October 28, 2020

Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial.

Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial.

Journal: Cancers

Published: July 23, 2020

Title Not Found

Title Not Found

Journal: Aktuelle Urologie

Published: March 28, 2018

Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring

Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring

Journal: Der Urologe. Ausg. A

Published: July 15, 2016

Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring

Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring

Journal: Der Urologe. Ausg. A

Published: May 09, 2014

Value of intermittent androgen deprivation in the context of the current data situation

Value of intermittent androgen deprivation in the context of the current data situation

Journal: Aktuelle Urologie

Published: July 27, 2013

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.

Journal: Prostate cancer and prostatic diseases

Published: July 09, 2013

Antigen-specific CD4 T cells are induced after intravesical BCG-instillation therapy in patients with bladder cancer and show similar cytokine profiles as in active tuberculosis.

Antigen-specific CD4 T cells are induced after intravesical BCG-instillation therapy in patients with bladder cancer and show similar cytokine profiles as in active tuberculosis.

Journal: PloS one

Published: May 02, 2013

Abiraterone in metastatic prostate cancer without previous chemotherapy.

Abiraterone in metastatic prostate cancer without previous chemotherapy.

Journal: The New England journal of medicine

Published: December 12, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026